Back to top

gene-therapy: Archive

Zacks Equity Research

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

CGENNegative Net Change HRTXNegative Net Change RCKTNegative Net Change ARQTNegative Net Change

Zacks Equity Research

Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.

BAYRYNegative Net Change CGENNegative Net Change ANVSPositive Net Change ALXONegative Net Change

Zacks Equity Research

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

ILMNPositive Net Change RMDPositive Net Change MEDPNegative Net Change HIMSNegative Net Change

Zacks Equity Research

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

RHHBYNegative Net Change PFENegative Net Change SRPTNegative Net Change RGNXNegative Net Change SLDBNegative Net Change

Kinjel Shah

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

JNJNegative Net Change PFENegative Net Change NVONegative Net Change LLYNegative Net Change

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

VRTXPositive Net Change EDITNegative Net Change CRSPNegative Net Change ALXONegative Net Change